150 related articles for article (PubMed ID: 18335586)
1. Eurofile. Private-public drive to cut delays in drug development.
Mundell I
Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
[No Abstract] [Full Text] [Related]
2. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
3. Firms seek new models to access public equity.
Mitchell P
Nat Biotechnol; 2009 Oct; 27(10):878-9. PubMed ID: 19816432
[No Abstract] [Full Text] [Related]
4. Facing the challenge: the symposium in context.
Widdus R
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S30-2. PubMed ID: 16087205
[No Abstract] [Full Text] [Related]
5. AIDS and the private sector.
Nature; 2006 Oct; 443(7113):723. PubMed ID: 17051166
[No Abstract] [Full Text] [Related]
6. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.
Wheeler C
Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375
[No Abstract] [Full Text] [Related]
7. The perils of subsidiarity.
Nat Biotechnol; 2004 Dec; 22(12):1483. PubMed ID: 15583638
[No Abstract] [Full Text] [Related]
8. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
9. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
Feinberg MB; Gordon L
Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
[No Abstract] [Full Text] [Related]
10. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
11. Human genomes, public and private.
Nature; 2001 Feb; 409(6822):745. PubMed ID: 11236960
[No Abstract] [Full Text] [Related]
12. Hard times: is this the end of the road for the private finance initiative?
Davies P
BMJ; 2010 Jul; 341():c3828. PubMed ID: 20647288
[No Abstract] [Full Text] [Related]
13. Public- and private-sector partnerships in contraceptive research and development: guiding principles.
Brooke S; Vail JG
Int J Gynaecol Obstet; 1999 Dec; 67 Suppl 2():S125-39. PubMed ID: 10661750
[TBL] [Abstract][Full Text] [Related]
14. The Human Genome Project: a public good.
Hudson K
Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
[No Abstract] [Full Text] [Related]
15. Bailing out.
Petsko GA
Genome Biol; 2011 Oct; 12(10):131. PubMed ID: 22035635
[No Abstract] [Full Text] [Related]
16. The borders of solidarity: how countries determine the public/private mix in spending and the impact on health care.
Flood CM; Stabile M; Tuohy CH
Health Matrix Clevel; 2002; 12(2):297-356. PubMed ID: 12430358
[No Abstract] [Full Text] [Related]
17. AAMC seeks public-private fund for medical education.
Pallarito K
Mod Healthc; 1993 Aug; 23(31):4. PubMed ID: 10127398
[No Abstract] [Full Text] [Related]
18. Australia's 'free-ride' in pharmaceuticals: can it last?
Kemp R
Aust Health Rev; 1996; 19(1):81-94. PubMed ID: 10157539
[TBL] [Abstract][Full Text] [Related]
19. Changing the public-private mix: an assessment of the health reforms in Greece.
Liaropoulos LL; Kaitelidou D
Health Care Anal; 1998 Dec; 6(4):277-85. PubMed ID: 10345933
[TBL] [Abstract][Full Text] [Related]
20. Private company profiles.
Nat Biotechnol; 2002 Jul; 20 Suppl():BE15-21. PubMed ID: 12089572
[No Abstract] [Full Text] [Related]
[Next] [New Search]
